Wedbush Remains Bullish on Carbylan Therapeutics (CBYL) Despite Mixed Cor1.1 Results - PT to $14
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/7/2026
- Wall Street ends lower as solid jobs data fuels hawkish Fed bets
- US nonfarm payrolls blow past expectations in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil ends week higher on renewed US-Iran strikes, diesel hits record
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Carbylan Therapeutics Reports Top-Line Results From COR1.1 Clinical Trial of Hydros-TA in Patients With OA of the Knee
February 1, 2016 4:01 PM ESTPALO ALTO, Calif., Feb. 01, 2016 (GLOBE NEWSWIRE) -- Carbylan Therapeutics (NASDAQ: CBYL), a specialty pharmaceutical company focused on the development of novel and proprietary combination therapies, today announced top-line results from COR1.1, its first Phase III trial of Hydros-TA for the treatment of pain associated with osteoarthritis of the knee. Hydros-TA is the companys proprietary formulation of hyaluronic acid which entraps a low-dose corticosteroid, triamcinolone acetonide (TA). Hydros contains the same proprietary hyaluronic acid without the addition of TA.Â
COR1.1 was a 560 patient, international, multi-center, randomized, double-blind study designed to... More
